|
| Refludan Description:
Refludan is indicated for patients who have had a reaction to heparin that resulted in reduced platelets and associated blood clots, in order to prevent more clotting complications.
Active Ingredient: lepirudin (rDNA)
Strength(s): 50mg/vial
Dosage Form(s): Injection |
Product Notes:
Who should not be treated with Refludan? You should not be given Refludan if you are allergic to this drug or similar drugs.
Special Warnings for Refludan:
Bleeding is the most common complication of Refludan. If you have the following conditions, your risk of bleeding may be increased:
Recent puncture of large vessels or organ biopsy
Abnormality of blood vessels or organs
Recent "mini-stroke," stroke, brain surgery, or other central nervous system procedure
Uncontrolled severe high blood pressure
Infection of the heart lining (endocarditis)
Advanced kidney damage
Tendency to bleed
Recent major surgery
Recent major bleeding
General Precautions with Refludan:
Your doctor will monitor your treatment by using a test that measures the clotting time of your blood.
The dosage of Refludan may be decreased if you have liver or kidney disease.
What should I tell my doctor or health care provider?
Because certain other medications can interact with Refludan, and increase the risk of bleeding, review all medications that you are taking with your health care provider, including those that you take without a prescription. Other drugs that break up or dissolve clots, such as (rt-PA) or streptokinase, or drugs that prevent clots such as Coumadin, warfarin, or aspirin, can increase your risk of bleeding. Side Effects:
Bleeding was the most common adverse event reported during testing of the product. Bleeding can be severe.
Other side effects occurring in at least 2% of the people studied:
Abnormal liver function
Allergic skin reactions Manufacturer link or canadian Pharmacy drug sources: na
|
